Omnes, Principia, Seventure in €46.3m series-E for Enterome

New investors SymBiosis, a microbiome-focused investment vehicle, and Takeda Pharmaceutical Company also took part in the round.

Seventure deployed part of the capital from its Health for Life Capital II fund, which has a €200m target and held a first close in March 2019.

In addition to the equity from its backers, Enterome has made a first drawdown from a loan facility provided by the European Investment Bank (EIB) under a 2018 agreement.

The company intends to us the fresh financing to progress the clinical development of its therapeutic pipeline, including the first clinical trials of EO2401, a novel OncoMimic cancer immunotherapy. 

Enterome will also use the proceeds to support its partner Takeda in delivering proof-of-concept clinical data with EB8018 (sibofimloc/TAK-018), an oral FimH blocker for the treatment of Crohn’s disease.

Previous funding
Seventure and Lundbeckfonden provided Enterome with a €5m series-A round of funding in March 2012.

Two years later, an €10m series-B round was raised by the company from Seventure, Lundbeckfonden and Omnes.

Subsequently, Seventure, Lundbeckfonden and Omnes, alongside Health for Life Capital and Nestlé Health Science, provided a €14.5m series-C round in April 2016.

More recently, Italian GP Principia and US-based pharmaceutical company Bristol-Myers Squibb led a €32m series-D round for Enterome in January 2018. Existing investors Seventure Partners, Health for Life Capital, Lundbeckfonden Ventures, Omnes Capital and Nestlé Health Science all took part in the round. In addition, the European Investment Bank (EIB) provided a €40m credit line to the company. 

Company
Established in 2012 and headquartered in Paris, with an additional office in Cambridge, US, Enterome discovers drugs for chronic medical conditions related to bacterial composition abnormalities.

The company’s first clinical candidate is EO2401, which was developed from Enterome’s OncoMimics, microbiome-derived peptide antigens that closely mimic antigens expressed by tumor cells. They are selected based on their ability to trigger the rapid activation of memory T-cells that respond to gut bacteria and to direct a targeted cell-killing immune response against the tumor. EO2401 combines three OncoMimics present in aggressive cancers such as glioblastoma and adrenal malignancies.

In addition, Enterome's second OncoMimic candidate, EO2463, a new multi-peptide cancer immunotherapy, is expected to enter the clinic in 2021 for the treatment of B-cell malignancies (lymphomas and leukaemias).

Enterome has partnerships with pharmaceutical companies and academic research institutes, including Johnson & Johnson Innovation, Janssen Biotech and the Mayo Clinic and Geisinger hospitals for metabolic disorders.

People
Enterome – Pierre Belichard (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• France
• Healthcare
• Venture
• Omnes Capital
• Principia
• Seventure (SPEF)
• France